

Ora[®] product supply shortage

Due to a manufacturing issue, Ora[®] products are likely to be in limited supply for the coming months before resupply in early November. These products include Ora-Blend[®], Ora-Blend SF[®], Ora-Plus[®], Ora-Sweet[®] and Ora-Sweet SF[®] - see <u>Pharmac website for current situation</u>.

Many of the New Zealand Compounding Working Group Standardised Batch Sheets for compounded oral liquids (hosted on the <u>PSNZ website</u>) use Ora[®] products.

In general, if your pharmacy is unable to obtain the Ora[®] product you normally use:

- 1. Check the standardised batch sheet on the PSNZ website to see if an alternative Ora[®] product can be used (e.g., if you normally use Ora-Blend[®], check if the sugar free version can be substituted).
- 2. If no alternative Ora[®] products can be used, or are available, check to see if the solid dose form can be dispersed in water (or crushed and mixed with water). The Australian reference 'Don't Rush to Crush' is available for <u>PSNZ members via AusDI</u> on their website. You may also consider seeking advice from one of the hospital-based medicines information services, or a paediatric pharmacist if related to a child under specialist care. Also discuss with the prescriber regarding unapproved methods of administration a new prescription may be needed.

Prioritisation of compounding

Where possible, remaining supplies of Ora[®] products should be prioritised for compounding liquids of these medicines that are high risk, and for use in infants and children:

- Azathioprine (due to risk when crushing tablets at home)
- Baclofen
- Clonidine
- Levothyroxine
- Sildenafil
- Tramadol

Next priority should be given to medicines that do not disperse easily or where the active ingredient is poorly water soluble and part doses are being used, or they are being administered via a feeding tube:

- Clobazam
- Diltiazem
- Enalapril
- Metoprolol tartrate
- Verapamil

New Zealand Compounding Working Group September 2023